×
ResMed Receivables 2010-2024 | RMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ResMed receivables for the quarter ending September 30, 2024 were
$0.811B
, a
17.16% increase
year-over-year.
ResMed receivables for 2024 were
$0.837B
, a
18.78% increase
from 2023.
ResMed receivables for 2023 were
$0.705B
, a
22.39% increase
from 2022.
ResMed receivables for 2022 were
$0.576B
, a
6.24% decline
from 2021.
View More
ResMed Receivables 2010-2024 | RMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ResMed receivables for 2024 were
$0.837B
, a
18.78% increase
from 2023.
ResMed receivables for 2023 were
$0.705B
, a
22.39% increase
from 2022.
ResMed receivables for 2022 were
$0.576B
, a
6.24% decline
from 2021.
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$203.2B
Stryker (SYK)
$148.2B
Boston Scientific (BSX)
$133.1B
EssilorLuxottica (ESLOY)
$113.5B
Medtronic (MDT)
$109B
Haleon (HLN)
$42.9B
Lonza Group Ag (LZAGY)
$42.1B
GE HealthCare Technologies (GEHC)
$37.7B
Terumo (TRUMY)
$29.2B
Koninklijke Philips (PHG)
$24.4B
Zimmer Biomet Holdings (ZBH)
$22.1B
Insulet (PODD)
$18.4B
Baxter (BAX)
$16.6B
Smith & Nephew SNATS (SNN)
$11.2B
BellRing Brands (BRBR)
$9.5B
Bio-Rad Laboratories (BIO)
$9B
Demant (WILYY)
$8.3B
Lantheus Holdings (LNTH)
$5.5B
TG Therapeutics (TGTX)
$4.7B
Haemonetics (HAE)
$4.3B
ICU Medical (ICUI)
$4.2B
Prestige Consumer Healthcare (PBH)
$4.1B
Perrigo (PRGO)
$3.7B
Envista Holdings (NVST)
$3.5B
Neogen (NEOG)
$3.3B
Agios Pharmaceuticals (AGIO)
$3.1B
Shandong Weigao Medical Polymer (SHWGF)
$3B
GN Store Nord (GNNDY)
$2.8B
QuidelOrtho (QDEL)
$2.6B
Warby Parker (WRBY)
$2.3B